These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
488 related articles for article (PubMed ID: 24210243)
21. [Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass]. Shipeng G; Yongning C; Yadi Z; Chanyuan LI; Qifan J Nan Fang Yi Ke Da Xue Xue Bao; 2019 Dec; 39(12):1393-1401. PubMed ID: 31907150 [TBL] [Abstract][Full Text] [Related]
22. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. Dochez V; Caillon H; Vaucel E; Dimet J; Winer N; Ducarme G J Ovarian Res; 2019 Mar; 12(1):28. PubMed ID: 30917847 [TBL] [Abstract][Full Text] [Related]
23. Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses? Yanaranop M; Anakrat V; Siricharoenthai S; Nakrangsee S; Thinkhamrop B Gynecol Obstet Invest; 2017; 82(1):47-53. PubMed ID: 27197526 [TBL] [Abstract][Full Text] [Related]
24. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. Van Gorp T; Veldman J; Van Calster B; Cadron I; Leunen K; Amant F; Timmerman D; Vergote I Eur J Cancer; 2012 Jul; 48(11):1649-56. PubMed ID: 22226481 [TBL] [Abstract][Full Text] [Related]
25. Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer. Dikmen ZG; Colak A; Dogan P; Tuncer S; Akbiyik F Eur J Gynaecol Oncol; 2015; 36(4):457-62. PubMed ID: 26390703 [TBL] [Abstract][Full Text] [Related]
26. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis. Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074 [TBL] [Abstract][Full Text] [Related]
27. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727 [TBL] [Abstract][Full Text] [Related]
28. The reference intervals for HE4, CA125 and ROMA in healthy female with electrochemiluminescence immunoassay. Yang J; Sa M; Huang M; Yang J; Xiang Z; Liu B; Tang A Clin Biochem; 2013 Nov; 46(16-17):1705-8. PubMed ID: 24012857 [TBL] [Abstract][Full Text] [Related]
29. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277 [TBL] [Abstract][Full Text] [Related]
30. MMP3 in Comparison to CA 125, HE4 and the ROMA Algorithm in Differentiation of Ovarian Tumors. Cymbaluk-Ploska A; Chudecka-Glaz A; Surowiec A; Pius-Sadowska E; Machalinski B; Menkiszak J Asian Pac J Cancer Prev; 2016; 17(5):2597-603. PubMed ID: 27268637 [TBL] [Abstract][Full Text] [Related]
31. HE4 and ROMA index in Czech postmenopausal women. Novotny Z; Presl J; Kucera R; Topolcan O; Vrzalova J; Fuchsova R; Betincova L; Rokyta Z Anticancer Res; 2012 Sep; 32(9):4137-40. PubMed ID: 22993374 [TBL] [Abstract][Full Text] [Related]
32. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Bandiera E; Romani C; Specchia C; Zanotti L; Galli C; Ruggeri G; Tognon G; Bignotti E; Tassi RA; Odicino F; Caimi L; Sartori E; Santin AD; Pecorelli S; Ravaggi A Cancer Epidemiol Biomarkers Prev; 2011 Dec; 20(12):2496-506. PubMed ID: 22028406 [TBL] [Abstract][Full Text] [Related]
33. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911 [TBL] [Abstract][Full Text] [Related]
34. Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China. Xu Y; Zhong R; He J; Ding R; Lin H; Deng Y; Zhou L; Li X; Jiang J; Bao Y; Luo X; Duan C Clin Biochem; 2016 Jan; 49(1-2):32-40. PubMed ID: 26285075 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women. Fujiwara H; Suzuki M; Takeshima N; Takizawa K; Kimura E; Nakanishi T; Yamada K; Takano H; Sasaki H; Koyama K; Ochiai K Tumour Biol; 2015 Feb; 36(2):1045-53. PubMed ID: 25326813 [TBL] [Abstract][Full Text] [Related]
36. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. Ortiz-Muñoz B; Aznar-Oroval E; García García A; Covisa Peris A; Perez Ballestero P; Sanchez Yepes M; Garcia Lozano T; Illueca Ballester C; García Garcia E Tumour Biol; 2014 Jul; 35(7):7249-58. PubMed ID: 24771264 [TBL] [Abstract][Full Text] [Related]
37. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis. Zhang L; Chen Y; Wang K Curr Probl Cancer; 2019 Apr; 43(2):135-144. PubMed ID: 30017407 [TBL] [Abstract][Full Text] [Related]
38. A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer. Stiekema A; Lok CA; Kenter GG; van Driel WJ; Vincent AD; Korse CM Gynecol Oncol; 2014 Mar; 132(3):573-7. PubMed ID: 24418200 [TBL] [Abstract][Full Text] [Related]
39. A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass. Kaijser J; Van Gorp T; Van Hoorde K; Van Holsbeke C; Sayasneh A; Vergote I; Bourne T; Timmerman D; Van Calster B Gynecol Oncol; 2013 May; 129(2):377-83. PubMed ID: 23360924 [TBL] [Abstract][Full Text] [Related]
40. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis. Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]